You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光(600673.SH):正籌劃重大資產出售事項 將不再從事醫藥相關產品的生產和銷售
格隆匯 08-31 18:44

格隆匯8月31日丨東陽光(600673.SH)公佈,公司正在籌劃重大資產出售事項,擬向廣東東陽光藥業有限公司及/或其控股子公司(“廣藥”)轉讓公司所持宜昌東陽光長江藥業股份有限公司(“標的公司”或“東陽光藥”)的不超過51.41%股權(“標的資產”)。

經初步研究和測算,預計該次交易可能構成《上市公司重大資產重組管理辦法》規定的重大資產重組。

東陽光藥是公司的控股子公司,專注於藥物開發、生產以及中國境內的藥物銷售等業務,產品涵蓋抗病毒、內分泌、心血管等疾病治療領域,主要包括:治療病毒性流感的藥品可威(磷酸奧司他韋)膠囊和可威顆粒;治療內分泌及代謝類疾病的藥品爾同舒(苯溴馬隆片);抗感染藥物琳羅星(莫西沙星片)、陽之克(克拉黴素緩釋片);治療心血管疾病的藥品歐美寧(替米沙坦片)、欣海寧(氨氯地平片)、奧美沙坦酯片。

2020年以來,受新冠肺炎疫情影響,民眾防護意識提升,流感傳播減少、醫院人流量明顯下降。因此,東陽光藥核心產品可威銷量出現明顯下降,東陽光藥整體業績出現較大幅度下滑。2021年,疫情因素的影響仍在持續,儘管東陽光藥已採取措施積極應對,但經營業績尚未出現好轉的跡象。

次交易是上市公司在經營環境突發變化中尋求的積極應對措施,次交易有利於提升上市公司質量,有利於保護廣大投資者權益。

通過次交易,上市公司將不再從事醫藥相關產品的生產和銷售;公司將在夯實現有的“高純鋁-電子光箔-電極箔-鋁電解電容器”的一體化電子新材料產業鏈、空調熱交換器產業鏈和氯氟循環經濟產業鏈相關業務的基礎上,深化相關產業鏈上下游的整合,積極在相關領域拓展新業務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account